Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07202572 · ClinicalTrials.gov registry record · NA
A Study Of Virtual Reality Vs Sham VR On Fibromyalgia
A NA study of Fibromyalgia, sponsored by Mayo Clinic.
- Active
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07202572: Active NA study of Fibromyalgia, sponsored by Mayo Clinic.
NCT07202572 is a NA study of Fibromyalgia that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 179-participant average among 76 other Fibromyalgia trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07202572, a NA study of Fibromyalgia, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand the therapeutic impact of VR on Fibromyalgia symptoms and potentially increase the scope of treatment options for patients suffering from Fibromyalgia.
Primary Outcome
The primary outcome is the change in Fibromyalgia Impact Questionnaire Revised (FIQR) score from baseline to post-intervention, comparing scores after sham VR and after active TRIPP VR meditation. FIQR ranges from 0-100 and higher scores indicate higher impact of the condition, ie are worse. FIQR will be measured at baseline, week 2, and week 4. For Sequence A, the sham VR score is taken at week 4; for Sequence B, at week 2. For Sequence A, the active VR score is at week 2; for Sequence B, at we
Conditions Studied
Interventions
- DEVICE TRIPP VR Meditation
- BEHAVIORAL Sham VR
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-09-29 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT07202572 still lists
NCT07202572 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 179-participant average among 76 other Fibromyalgia trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Fibromyalgia appearing as the primary indexed condition, and to 2 interventions - of which TRIPP VR Meditation is the first listed.
NCT07202572 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07202572 about?
NCT07202572 is a clinical study titled "A Study Of Virtual Reality Vs Sham VR On Fibromyalgia". The purpose of this study is to understand the therapeutic impact of VR on Fibromyalgia symptoms and potentially increase the scope of treatment options for patients suffering from Fibromyalgia.
What is the current status of trial NCT07202572?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-09-29. Estimated completion is 2026-12-31.
What conditions does trial NCT07202572 study?
This clinical trial studies the following conditions: Fibromyalgia.
What interventions are being tested in trial NCT07202572?
The interventions under investigation include: TRIPP VR Meditation (DEVICE), Sham VR (BEHAVIORAL).
Who is sponsoring clinical trial NCT07202572?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07202572 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibromyalgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07202572's enrollment target sits among peer trials
40 54th of 76 higher than 21 of 76 other Fibromyalgia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fibromyalgia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Auricular Neuromodulation in Veterans With Fibromyalgia
RECRUITING · NA
-
Effects of Breathing and Attention Training (BAT) on Pain Modulation
RECRUITING · NA
-
Neural Mechanisms of Light Driven Analgesia
RECRUITING · NA
-
Fibromyalgia Sleep A to ZZZ Study
RECRUITING · NA
-
Explosive Synchronization of Brain Network Activity in Chronic Pain
RECRUITING · NA
-
Brief Pain Exposure Therapy (BPET) For Nociplastic Pain
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI